on the medical use of the drug. Vinpocetine ampoules, instructions for use

Active agent:
Vinpocetine
Dosage form:
Tablets 5mg №30
Leave rule:
On prescription
Vinpocetine-Astrapharm improves blood circulation and brain metabolism due to a complex mechanism of action. Selectively enhances cerebral blood flow: increases the cerebral fraction of minute volume, reduces the resistance of cerebral vessels without a significant effect on the parameters of systemic circulation, with virtually no effect on blood pressure, minute volume, pulse rate, total peripheral vascular resistance; when used, it primarily increases the blood supply to ischemic patients areas of the brain. Increases the supply of oxygen and glucose to the brain, increases the resistance of brain cells to hypoxia, has a neuroprotective (cerebroprotective) effect in relation to nervous tissue. Inhibits platelet aggregation and adhesion, reduces blood viscosity, helps normalize venous outflow against the background of reduced resistance cerebral vessels, improves rheological properties blood and microcirculation in the brain tissue, has an antioxidant effect. Increases the elasticity of red blood cells and inhibits their absorption of adenosine. Under the influence of Vinpocetine-Astrapharm, the affinity of hemoglobin for oxygen and the additional transport of the latter increase. It expands the vessels of the brain, which is directly related to the direct relaxing effect on the smooth muscles of the vessels, mainly the brain. AT acute period stroke accelerates the regression of cerebral symptoms, improves memory, attention, intellectual productivity. Increases the content of catecholamines in brain tissues. In elderly people, the sensitivity of cerebral vessels to the action of Vinpocetine-Astrapharm increases.
Indications
Acute and chronic disorder cerebral circulation(transient cerebral ischemia, cerebral stroke, post-stroke condition). Atherosclerosis. neurological and mental disorders in patients with cerebrovascular insufficiency (memory impairment, syncope, aphasia, apraxia, movement disorders, headache). Encephalopathy (hypertensive, post-traumatic). Vasovegetative symptoms in menopause. Vascular diseases eyes caused by atherosclerosis, angiospasm of retinal vessels, degenerative diseases of the retina or yellow spot, arterial and venous thromboses or embolism, secondary glaucoma. Decrease in hearing acuity, vascular or toxic genesis, senile hearing loss, Meniere's disease, cochleovestibular neuritis, tinnitus, syncope of labyrinthine origin.
Mode of application
Adults take 1 - 2 tablets (5 mg) 3 times a day after meals (maximum daily dose- 30 mg). For maintenance therapy, take 1 tablet 3 times a day. The duration of the course of treatment is 2 months. Therapeutic effect seen after about 1 to 2 weeks.
Interaction with drugs
Contraindications
Hypersensitivity to active substance or other components of the drug, pronounced violations heart rate, ischemic disease hearts ( severe course), acute stage hemorrhagic stroke, increased intracranial pressure, pregnancy, lactation. The drug is not prescribed under the age of 18 due to insufficient experience in the use of Vinpocetine-Astrapharm.

active substance: vinpocetine;

1 tablet contains vinpocetine 5 mg;

Excipients: lactose, monohydrate; corn starch; magnesium stearate.

Dosage form

Basic physical and chemical properties: tablets white color flat-cylindrical shape with bevelled edges and a dash.

Pharmacotherapeutic group

Psychostimulants and nootropics. ATX code N06B X18.

Pharmacological properties

Pharmacodynamics.

Vinpocetine has a complex mechanism of action, favorably affecting cerebral circulation and cerebral metabolism, and also improves the rheological properties of blood.

Vinpocetine has neuroprotective effects: drug weakens harmful action cytotoxic reactions caused by stimulatory amino acids. The drug inhibits voltage-dependent Na + - and Ca 2+ -channels, as well as NMDA and AMPA receptors. The drug enhances the neuroprotective effect of adenosine.

Vinpocetine stimulates cerebral metabolism: the drug increases the uptake of glucose and O 2 and the consumption of these substances by brain tissue. The drug increases the resistance of the brain to hypoxia; increases the transport of glucose - an exclusive source of energy for the brain - through the blood-brain barrier; shifts glucose metabolism towards an energetically more favorable aerobic pathway; selectively inhibits Ca 2+ -calmodulin-dependent enzyme cGMP-phosphodiesterase (PDE); increases the levels of cAMP and cGMP in the brain. The drug increases the concentration of ATP and the ratio of ATP / AMP; enhances the exchange of norepinephrine and serotonin in the brain; stimulates the ascending noradrenergic system; has antioxidant activity, as a result of all the above effects, vinpocetine has a cerebroprotective effect.

Vinpocetine improves microcirculation in the brain: the drug inhibits platelet aggregation, reduces pathological increased viscosity blood, increases the ability of red blood cells to deform and inhibits the uptake of adenosine; improves the transport of O 2 in tissues by reducing the affinity of O 2 to erythrocytes.

Vinpocetine selectively increases blood flow in the brain: the drug increases the cerebral fraction of cardiac output; reduces vascular resistance in the brain without affecting systemic circulation parameters (blood pressure, cardiac output, pulse rate, total peripheral resistance); the drug does not cause a “stealing effect”. Moreover, while taking the drug, blood flow improves in damaged (but not yet necrotic) ischemic areas with low perfusion (" reverse effect robbery").

Pharmacokinetics.

Vinpocetine is rapidly absorbed, the maximum plasma concentration is reached 1 hour after oral administration. The main site of absorption of vinpocetine is the proximal digestive tract. The compound does not experience metabolism at the time of passage through the intestinal wall.

Binding to blood proteins is 66%. The absolute bioavailability of vinpocetine when taken orally is 7%. The volume of distribution is 246.7 ± 88.5 l, which means a pronounced binding of the substance in the tissues. The clearance value of vinpocetine in blood plasma exceeds its value in the liver, which indicates extrahepatic metabolism of the compound.

With repeated oral administration of the drug at a dose of 5 mg and 10 mg, vinpocetine demonstrates linear kinetics. The half-life is 4.83±1.29 hours. The main route of excretion of the drug is carried out by the kidneys and through the intestines in a ratio of 60:40%.

The main metabolite of vinpocetine is apovincamic acid (AVA), which in humans is formed in 25-30%. After oral administration, the area under the concentration-time curve of VKA is 2 times higher than the same after intravenous administration drug, which indicates the formation of VKA in the process of first pass metabolism of vinpocetine. The amount of vinpocetine excreted unchanged was only a few percent of taken dose drug.

An important and significant property of vinpocetine is the absence of the need for a special selection of the dose of the drug for patients with liver or kidney diseases, given the metabolism of the drug and the absence of cumulation (accumulation).

The kinetics of vinpocetine in elderly patients does not differ significantly from the kinetics of vinpocetine in young people and, in addition, there is no cumulation.

Clinical Characteristics

Indications

Neurology. For treatment various forms cerebrovascular pathology: conditions after suffering a cerebrovascular accident (stroke), vertebrobasilar insufficiency, vascular dementia, cerebral atherosclerosis, post-traumatic and hypertensive encephalopathy. Helps to reduce mental and neurological symptoms in cerebrovascular pathology.

Ophthalmology. For the treatment of chronic vascular pathology choroid eyes and retinas.
Otorhinolaryngology. For the treatment of perceptual hearing loss, Meniere's disease and tinnitus.

Contraindications

Hypersensitivity to vinpocetine or to any component of the drug. Severe coronary heart disease, cardiac arrhythmias. The period of pregnancy or lactation. Childhood.

Interaction with other drugs and other types of interactions.

The simultaneous use of Vinpocetine-Astrapharm with b-blockers (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol or hydrochlorothiazide was not accompanied by any interaction between them. In isolated cases, some additional effect was observed with the simultaneous use of a-methyldopa and vinpocetine, therefore, against the background of the use of this combination of drugs, it is necessary to carry out regular monitoring blood pressure.

Although the data clinical research did not confirm the interaction, it is recommended to be careful in case of simultaneous use of vinpocetine with medicines affecting the central nervous system, as well as in the case of concomitant antiarrhythmic and anticoagulant therapy.

Application features

If the patient has increased intracranial pressure, arrhythmia or long QT interval syndrome, as well as against the background of the use of antiarrhythmic drugs, the course of therapy with the drug can be started only after a thorough analysis of the benefits and risks associated with the use of the drug.

The drug contains lactose, so it should not be prescribed to patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.

Reproductivity. Does not affect fertility.

Teratogenic action not found.

Mutagenicity. Vinpocetine is not mutagenic.

Carcinogenicity. Vinpocetine is not carcinogenic.

Use during pregnancy or lactation.

Contraindicated.

The ability to influence the reaction rate when driving vehicles or operating other mechanisms.

When using the drug, there may be side effects from the central nervous system therefore, care must be taken when driving vehicles or working with other mechanisms.

Dosage and administration

Tablets are taken orally after meals.

The dose for adults is 5-10 mg 3 times a day (15-30 mg).

With diseases of the liver and / or kidneys special selection dose is not needed.

The duration of treatment is determined by the doctor individually.

Children.

Children do not use the drug (due to lack of clinical data).

Overdose

There were no cases of overdose. Long-term use vinpocetine at a daily dose of 60 mg is also safe. Even a single oral dose of 360 mg of vinpocetine did not cause any clinically significant unwanted effect from the side of cardio-vascular system or other effects.

Adverse reactions

From the blood and lymphatic system: rarely - leukopenia, thrombocytopenia; very rarely - anemia, agglutination of red blood cells.

From the side immune system: very rarely - hypersensitivity.

Metabolic disorders: infrequently - hypercholesterolemia; rarely - loss of appetite, anorexia, diabetes.

From the side of the psyche: rarely - insomnia, sleep disturbance, anxiety; very rarely - euphoria, depression.

From the nervous system: infrequently - headache; rarely - dizziness, dysgeusia, stupor, hemiparesis, drowsiness, amnesia; very rarely - tremor, convulsions, agitation.

From the side of the organs of vision: rarely - swelling of the nipple optic nerve; very rarely - conjunctival hyperemia.

From the hearing organs: infrequently - vertigo; rarely - hyperacusis, hypoacusis, tinnitus.

From the side of the cardiovascular system: infrequently - arterial hypotension; rarely - ischemia / myocardial infarction, angina pectoris, bradycardia, tachycardia, extrasystole, palpitations, arterial hypertension, hot flashes, thrombophlebitis; very rarely - arrhythmias, atrial fibrillation, changes in blood pressure, ST segment depression, prolongation of the QT interval, but the presence causation between such a side effect and treatment with vinpocetine has not been proven, since these symptoms are observed with the same frequency in the natural population.

From the digestive tract: infrequently - discomfort in the abdomen, dry mouth, nausea; rarely - abdominal pain, constipation, diarrhea, dyspepsia, vomiting; very rarely - dysphagia, stomatitis, heartburn.

From the skin and subcutaneous tissue: rarely - erythema, hyperhidrosis, itching, urticaria, rash; very rarely - dermatitis.

General violations: rarely - asthenia, weight gain, general weakness(symptoms may be manifestations of the underlying disease), sensation of heat, fatigue; very rarely - discomfort in chest, hypothermia.

Laboratory research: infrequently - a decrease in blood pressure; rarely - an increase in blood pressure, an increase in the level of triglycerides in the blood, depression of the ST segment on the electrocardiogram, an increase / decrease in the number of eosinophils, a change in the activity of liver enzymes; very rarely - an increase / decrease in the number of leukocytes, a decrease in the number of erythrocytes, a decrease in prothrombin time.

Best before date

Storage conditions

Store in original packaging at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Package

10 tablets in a blister; 2 or 3 or 5 blisters in a box.

Holiday category

On prescription.

Manufacturer

ASTRAPHARM LLC.

The location of the manufacturer and the address of the place of its activity.

Ukraine, 08132, Kyiv region, Kiev-Svyatoshinsky district, Vyshneve, st. Kyiv, 6.

End of text official instructions

/ Vinpocetine-astrafarm

Active agent:
Vinpocetine
Dosage form:
Tablets 5mg №30
Leave rule:
On prescription
Vinpocetine-Astrapharm improves blood circulation and brain metabolism due to a complex mechanism of action. Selectively enhances cerebral blood flow: increases the cerebral fraction of minute volume, reduces the resistance of cerebral vessels without a significant effect on the parameters of systemic circulation, with virtually no effect on blood pressure, minute volume, pulse rate, total peripheral vascular resistance; when used, it primarily increases the blood supply to ischemic patients areas of the brain. Increases the supply of oxygen and glucose to the brain, increases the resistance of brain cells to hypoxia, and has a neuroprotective (cerebroprotective) effect on the nervous tissue. It inhibits platelet aggregation and adhesion, reduces blood viscosity, promotes the normalization of venous outflow against the background of a decrease in the resistance of cerebral vessels, improves the rheological properties of blood and microcirculation in the brain tissue, and has an antioxidant effect. Increases the elasticity of red blood cells and inhibits their absorption of adenosine. Under the influence of Vinpocetine-Astrapharm, the affinity of hemoglobin for oxygen and the additional transport of the latter increase. It expands the vessels of the brain, which is directly related to the direct relaxing effect on the smooth muscles of the vessels, mainly the brain. In the acute period of a stroke, it accelerates the regression of cerebral symptoms, improves memory, attention, and intellectual productivity. Increases the content of catecholamines in brain tissues. In elderly people, the sensitivity of cerebral vessels to the action of Vinpocetine-Astrapharm increases.
Indications
Acute and chronic cerebrovascular accident (transient cerebral ischemia, cerebral stroke, post-stroke condition). Atherosclerosis. Neurological and mental disorders in patients with cerebrovascular insufficiency (memory disorders; syncope; aphasia, apraxia, movement disorders, headache). Encephalopathy (hypertensive, post-traumatic). Vasovegetative symptoms in menopause. Vascular diseases of the eye caused by atherosclerosis, angiospasm of retinal vessels, degenerative diseases of the retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma. Decrease in hearing acuity, vascular or toxic genesis, senile hearing loss, Meniere's disease, cochleovestibular neuritis, tinnitus, syncope of labyrinthine origin.
Mode of application
Adults take 1-2 tablets (5 mg) 3 times a day after meals (the maximum daily dose is 30 mg). For maintenance therapy, take 1 tablet 3 times a day. The duration of the course of treatment is 2 months. The therapeutic effect is observed after about 1 - 2 weeks.
Interaction with drugs
Contraindications
Hypersensitivity to the active substance or other components of the drug, severe cardiac arrhythmias, coronary heart disease (severe course), acute stage of hemorrhagic stroke, increased intracranial pressure, pregnancy, lactation. The drug is not prescribed under the age of 18 due to insufficient experience in the use of Vinpocetine-Astrapharm.

Vinpocetine-astrafarm Full information by drug. Vinpocetine-astrafarm Pharmacology, indications for use, contraindications, method of application, side effects, Vinpocetine-astrafarm drug interaction, pregnancy, overdose, release form, storage conditions, composition.

• The composition of 1 tablet of Vinpocetine, depending on the manufacturer, may include 5 or 10 mg of the active ingredient of the same name. Additional substances: potato starch, colloidal silicon dioxide, lactose, magnesium stearate.
• 1 ml of solution concentrate for infusion contains 5 mg vinpocetine . Additional substances: hydrochloric acid, propylene glycol, sodium disulfite, disodium edetate, sodium sulfite, lemon acid, water.

Release form

White or light yellow round biconvex tablets with a serif on one side. 10/20/30/50/100 tablets in blister packs, from 1 to 10 packs in a cardboard box.

The concentrate is a clear, slightly colored solution. 2/5 ml in a dark glass ampoule, 5/10 ampoules in a cell pack, 1 or 2 packs in a cardboard box.

pharmachologic effect

According to OKPD - a drug that affects the central nervous system. It enhances cerebral circulation, has antihypoxic, antiaggregatory, vasodilating effects.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

INN - Vinpocetine. A drug that enhances cerebral circulation and. Suppresses activity phosphodiesterase , causing accumulation cAMP in tissues. It demonstrates a vasodilating effect mainly on the vessels of the brain, which is due to an antispasmodic myotropic effect. Systemic blood pressure decreases slightly.

Stimulates blood supply to brain tissues, reduces platelet aggregation, regulates the rheological properties of blood. Improves resistance to hypoxia of brain cells, stimulating the transfer of oxygen to tissues due to a decrease in the tropism of red blood cells to it, activating metabolism and glucose uptake. Increases concentration catecholamines in brain cells.

Pharmacokinetics

When ingested, it is rapidly absorbed from the intestine. The highest concentration in the blood is reached after about 1 hour. The half-life reaches 5 hours.

Vinpocetine indications for use

Indications for use Vinpocetine Forte and Vinpocetine are identical.

What are Vinpocetine tablets for?

The use of the drug according to the instructions is justified when:

• failure cerebral circulation acute or chronic;
• post-traumatic;
• encephalopathy , provoking dizziness, memory impairment, headache;
• vascular lesions of the choroid and retina;
• against the background of climacteric syndrome;
• hearing loss of vascular or toxic origin, dizziness of labyrinthine origin, Meniere's disease .

Indications for use Vinpocetine Acry:

• to reduce the severity and strength of neurological and mental signs at different forms insufficiency of cerebral circulation (consequences, recovery stage stroke , temporary ischemic attack , insufficiency of vertebrobasilar circulation, vascular genesis, cerebral arteries, encephalopathy post-traumatic and hypertensive genesis);
• Meniere's disease , perceptual hearing loss, tinnitus of unknown origin;
• chronic vascular lesions of the choroid and retina.

Contraindications

• Acute hemorrhagic stroke , expressed or cardiac ischemia .
• on any of the components of the drug.
• Pregnancy or lactation.
• Age less than 18 years.

Side effects

Side effects are the same for Vinpocetine and other drugs with a similar composition.

• Reactions from blood circulation: increased heart rate, instability of blood pressure, change ECG , extrasystole , tides.
• Reactions from nervous activity : dizziness, headache .
• Reactions from digestion: nausea, dry mouth, .
• Other reactions: weakness, allergic reactions , increased sweating.

Application instruction of Vinpocetine (Way and dosage)

Vinpocetine tablets, instructions for use

For oral administration, tablets with a dosage of 5-10 mg are usually used, which are taken from 1 to 3 times a day, depending on the type of pathology and the doctor's recommendations.

Instructions for use Vinpocetine Acry

The medicine should be taken after meals, inside, 1 tablet three times a day. Initial daily dosage- 15 mg. The highest daily dosage is 30 mg. The duration of the course of treatment, depending on the recommendations of the doctor, can reach 3 months.

In case of disorders of kidney or liver function, the dosage of the drug is not changed.

The dose is reduced gradually until complete abolition.

Vinpocetine ampoules, instructions for use

In the form of injections, Vinpocetine IV is mainly used at acute conditions , a single dose is 20 mg. With normal tolerance, the dosage is increased after 3-4 days to 1 mg / kg of body weight. The duration of therapy is usually 10-14 days.

Overdose

Signs of an overdose: increased severity of undesirable effects.

Overdose treatment: gastric lavage, ingestion enterosorbents , symptomatic treatment.

Interaction

Interactions have not been identified with simultaneous use with, β-blockers , Acenocoumarol , .

In some cases it is required joint application With Methyldopa , from which the drug sometimes causes a hypotensive effect. With this treatment, regular monitoring of blood pressure is necessary.

There are no data to support drug interactions with drugs central action, antiarrhythmic drugs and anticoagulants, therefore, it is recommended to be careful with such simultaneous administration.

The drug increases the risk of hemorrhagic complications in simultaneous heparin therapy .

Terms of sale

On prescription.

Storage conditions

Store in a dark dry place with room temperature. Keep away from children.

Best before date

special instructions

The drug should be used with caution when , arrhythmias , unstable pressure and reduced vascular tone.

Parenteral drug in acute cases apply until the patient's condition improves, then switch to oral administration. At chronic disorders the drug is also taken orally.

At cerebral hemorrhagic stroke intravenous administration of the drug is allowed only after the relief of acute events.

Vinpocetine analogs

Coincidence in the ATX code of the 4th level:

Vinpocetine analogs: Vicebrol, Neurovin, Oxopotin,.

Synonyms

Vinpocetine Forte, Vinpocetine-Akos, Vinpocetine Akri, Vinpocetine-Sar.

children

For children under 18 years of age, the drug is prohibited for use.

During pregnancy and lactation

The drug is prohibited for use during pregnancy (due to the risk placental bleeding and sudden as a result of stimulation of the placental blood supply) and during lactation.

Vinpocetine Reviews

Reviews of Vinpocetine Akri and reviews of Vinpocetine Forte and Vinpocetine are fundamentally similar and perfectly characterize therapeutic properties these drugs. Most often, the drug is used to improve the blood supply to the brain. Reviews of doctors on the forum indicate a rare occurrence side effects and recommend that you start taking the drug only as directed. medical worker. children this drug prohibited.

Vinpocetine price, where to buy

The price of Vinpocetine tablets in Russia is 130-210 rubles, depending on the manufacturer, and the price Vinpocetine Forte 10 mg No. 30 - 85-90 rubles. Price ampoules the drug for 2 ml No. 10 approaches 65 rubles.

The average price of such tablets in Ukraine in the above form of release is 31 hryvnia. Average prices of medicines with the prefix Forte and injection form drug (locally produced) in Ukraine are 104 and 28 hryvnia, respectively.

• Internet pharmacies in Russia Russia
• Internet pharmacies of Ukraine Ukraine
• Internet pharmacies of Kazakhstan Kazakhstan

WER.RU

Vinpocetine 10mg N30 tab. Izvarino PharmaIzvarino Pharma LLC

Vinpocetine tablets 5 mg 50 pcs. IzvarinoIzvarino Pharma LLC

Vinpocetine-OBL tablets 10 mg 30 pcs. Obolenskoe Obolenskoye FP

Vinpocetine tablets 5 mg 50 pcs. UpdateRenewal [Update]

Vinpocetine-OBL tablets 5 mg 50 pcs. Obolenskoe Obolenskoye FP

Europharm * 4% discount with promo code medical11

Vinpocetine-gedeon 5 mg 50 tablOJSC Gedeon Richter

Vinpocetine Covex 5 mg 50 tabl Kovex

Vinpocetine-obl 5 mg 50 tab.Obolenskoye FP CJSC

Vinpocetine forte 10 mg 30 tabl Ozone LLC

Vinpocetine 5 mg 50 tablets RenewalUpdate PFC JSC

Pharmacy Dialog * discount 100 rubles. by promo code medside(for orders over 1000 rubles)

Vinpocetine Forte Canon tablets 10mg №30

Vinpocetine-Astrapharm(Vinpocetine-Astrapharm)

international and chemical name: vinpocetine; apovincamic acid ethyl ester;

Basic physical and chemical characteristics: tablets of white color of a flat-cylindrical form with beveled edges and a notch on one side;

Compound. 1 tablet contains vinpocetine 5 mg;

other ingredients: lactose, corn starch, magnesium stearate.

The release form of the drug. Tablets.

Pharmacotherapeutic group.

Psychostimulants and nootropics. ATC code N06BX18.

The action of the drug. Pharmacodynamics. Vinpocetine-Astrapharm, an ethyl ester of apovincaminoic acid, is a drug that improves blood circulation and brain metabolism due to a complex mechanism of action.

Vinpocetine-Astrapharm selectively enhances cerebral blood flow: increases the cerebral fraction of minute volume, reduces the resistance of cerebral vessels without a significant effect on the parameters of systemic circulation, with virtually no effect on blood pressure, minute volume, pulse rate, general peripheral vascular resistance; does not produce the phenomenon of "deprivation", on the contrary, when it is used, the blood supply to ischemic, but still viable areas of the brain with low perfusion increases first of all.

Vinpocetine-Astrapharm increases the supply of oxygen and glucose to the brain. Increases the resistance of cells to hypoxia, facilitating the transport of oxygen to tissues, slowing down tissue and metabolic disorders caused by insufficient blood supply brain.

By increasing the use of glucose and oxygen, as well as improving aerobic metabolism, the drug has a neuroprotective (cerebroprotective) effect on nervous tissue under hypoxic conditions.

By activating adenylate cyclase and inhibiting phosphodiesterase, it increases the concentration of cAMP, ATP and ADP in brain cells.

At the same time, Vinpocetine-Astrapharm inhibits platelet aggregation and adhesion, reduces blood viscosity, promotes erythrocyte deformity and normalization of venous outflow against the background of a decrease in cerebral vascular resistance, improves blood rheology and microcirculation in the brain tissue, and has an antioxidant effect.

Increases the elasticity of red blood cells and inhibits their absorption of adenosine. Under the influence of Vinpocetine-Astrapharm, the affinity of hemoglobin to oxygen and the additional transport of the latter increase.

It expands the vessels of the brain, which is directly related to the direct relaxing effect on the smooth muscles of the vessels, mainly of the brain. It inhibits the activity of Ca +2 - calmodulin-depending on cGMP-phosphodiesterase and increases the level of cGMP in smooth muscle blood vessels, causing them to relax.

In the acute period of a stroke, it accelerates the regression of cerebral symptoms, improves memory, attention, and intellectual productivity.

Increases the content of catecholamines in brain tissues.

In elderly people, the sensitivity of cerebral vessels to the action of Vinpocetine-Astrapharm increases.

Pharmacokinetics. After oral administration, vinpocetine is well absorbed in the digestive tract, reaching a maximum concentration after 1 hour. Bioavailability is 70%. Vinpocetine has an elimination half-life of 4.8 hours. Therapeutic concentration of the drug in plasma is from 10 to 20 ng / ml. Easily penetrates barriers (including the blood-brain barrier), excreted in breast milk.

Biotransformed in the liver. The main metabolite is apovincamic acid. Excreted in the urine: a small amount - unchanged, the rest - in the form of metabolites.

Indications for use. Acute and chronic cerebrovascular accident (transient cerebral ischemia, cerebral stroke, post-stroke condition).

Neurological and mental disorders in patients with cerebrovascular insufficiency (memory impairment; dizziness; aphasia, apraxia, movement disorders, headache).

Encephalopathy (hypertensive, post-traumatic).

Vasovegetative symptoms in menopause.

Vascular diseases of the eye caused by atherosclerosis, angiospasm of retinal vessels, degenerative diseases of the retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma.

Decreased acuity of hearing, vascular or toxic origin, senile hearing loss, Meniere's disease, cochleovestibular neuritis, tinnitus, dizziness of labyrinthine origin.

Application and doses of the drug. Adults are prescribed 1-2 tablets (5 mg) of Vinpocetine-Astrafarma 3 times a day after meals (maximum daily dose is 30 mg). For maintenance therapy, use 1 tablet 3 times a day. The duration of the course of treatment is 2 months.

The effect of the treatment is observed after approximately 1 to 2 weeks.

Side effect. From the side of the cardiovascular system: a transient decrease in blood pressure, occasionally - tachycardia, extrasystole. It is also possible to increase the excitation time of the ventricle - the QT interval.

From the side of the central nervous system: occasionally - sleep disturbance, dizziness, headache, weakness.

From the digestive tract: dry mouth, nausea, heartburn.

Contraindications. Hypersensitivity to the active substance or other components of the drug, severe cardiac arrhythmias, coronary heart disease (severe course), acute stage of hemorrhagic stroke, increased intracranial pressure, pregnancy, lactation. Do not administer to children under the age of 18 due to insufficient experience in using Vinpocetine-Astrapharm.

Overdose. No cases of drug overdose have been reported.

Features of use.

Pharmacokinetic parameters are practically the same in young people and in the elderly. There is no need to adjust the dose in case of liver or kidney disease, including long-term use of Vinpocetine-Astrapharm.

Due to the fact that Vinpocetine-Astrapharm slows down the reaction, the patient should not work on machinery and drive a car during the period of drug use, the drug is not compatible with alcohol.

Prescribing the drug to patients with an increased QT interval should be avoided, because they are the most high risk development of arrhythmias. It is necessary to do an ECG in patients with this syndrome, as well as in patients who use drugs that can increase the QT interval.

Use with caution in patients with a history of prerequisites for sensitivity to other dye alkaloids, and in patients with renal insufficiency.

Vinpocetine-Astrapharm contains lactose, which must be taken into account when prescribing the drug to patients with lactose deficiency.

Interaction with other drugs. Despite the fact that the data of the experiments performed do not indicate any clinically significant interaction with other drugs, interaction with antihypertensive, antiarrhythmic drugs and anticoagulants (heparin and warfarin) is not excluded. Therefore, it is necessary to carefully examine patients who use Vinpocetine-Astrapharm and any of the above drugs.

Terms and conditions of storage.

Keep out of the reach of children, dry, dark place at a temperature not exceeding 25°C.

Shelf life - 5 years.